Stocktwits on MSN
IBRX stock jumps overnight after major FDA review win for Anktiva in bladder cancer
The FDA will review the expansion of Anktiva plus BCG to patients with papillary-only bladder cancer, with a final decision expected by Jan.6, 2027. ・The acceptance reversed last year’s FDA refusal-to ...
The FDA is reviewing an sBLA for nogapendekin alfa inbakicept-pmln plus BCG to treat BCG-unresponsive NMIBC with papillary disease without CIS.
CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...
Anktiva plus BCG aims to treat BCG-unresponsive NMIBC with papillary disease, potentially reducing radical cystectomy need. The treatment showed high rates of surgery avoidance and disease-free ...
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug ...
The MarketWatch News Department was not involved in the creation of this content. -- Following discussions with the U.S. FDA, the Agency recommended that the Company submit additional information for ...
The TAR-200 system offering sustained intravesical gemcitabine release shows favorable response and tolerability in both the CIS and papillary-only subgroups with BCG-unresponsive high-risk NMIBC. TAR ...
Oral presentation provides update from QUILT-3.032 on durable complete responses to ANKTIVA® plus BCG in BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ (NMIBC CIS) with or ...
Zacks Investment Research on MSN
FDA accepts IBRX's filing seeking expanded use of bladder cancer therapy
Shares of ImmunityBio IBRX were up 3% in after-market trading yesterday after the company announced that the FDA accepted its ...
Ferring Pharmaceuticals today announced a new real-world case series demonstrating that re-induction with ADSTILADRIN ® (nadofaragene firadenovec-vncg) resulted in complete responses (CR) in ...
ImmunityBio's stock is moving higher after the FDA announced it would review a possible label expansion for the company's ...
CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it recently held a Type B End-of-Phase meeting with the U.S. FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results